Treatment of Clostridium difficile infection in pediatric patients

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 6, 2015, Pages 747-755

  Esposito, Susanna ^a   Umbrello, Giulia ^a   Castellazzi, Luca ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibiotic therapy; children; Clostridium difficile; fecal microbiological transplantation; gastrointestinal infection; Probiotics

Indexed keywords

ACTOXUMAB; BACTERIAL VACCINE; BEZLOTOXUMAB; CLOSTRIDIUM TOXIN; FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ASYMPTOMATIC INFECTION; BACTERIAL COLONIZATION; BIFIDOBACTERIUM BREVE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLOSTRUM; DRUG CHOICE; FECAL MICROBIOLOGICAL TRANSPLANTATION; FECES MICROFLORA; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LEUKOCYTE COUNT; NONHUMAN; RECURRENT INFECTION; REVIEW; SACCHAROMYCES BOULARDII; SALVAGE THERAPY; TRANSPLANTATION; ADOLESCENT; ADVERSE EFFECTS; AGE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FECES; INFANT; INTESTINE; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FECES; HUMANS; INFANT; INTESTINES; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84929871851     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1039988     Document Type: Review

References (80)

1. Schwartz KL, Darwish I, Richardson SE, et al. Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr 2014;14:28
2. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93
3. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8
4. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122:1266-70
5. Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014;133:651-8
6. Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011;30:580-4
7. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010;31:754-9
8. Vande Wetering MD, Kuijpers TW, Taminiau JA, et al. Pseudomembranous and neutropenic enterocolitis in pediatric oncology patients. Support Care Cancer 2003;11:581-6
9. Castagnola E, Battaglia T, Bandettini R, et al. Clostridium difficile-associated disease in children with solid tumors. Support Care Cancer 2009;17:321-4
10. Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr 2015;60:18-22
11. Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011;165:451-7
12. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70
13. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
14. Rea MC, O'Sullivan O, Shanahan F, et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 2012;50:867-75
15. Hourigan SK, Chirumamilla SR, Ross T, et al. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2744-452
16. Larson HE, Barclay FE, Honour P, Hill ID. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982;146:727-33
17. Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun 1982;35: 895-9
18. Matsuki S, Ozaki E, Shozu M, et al. Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol 2005;8: 43-8
19. Bacon AE, Fekety R, Schaberg DR, Faix RG. Epidemiology of Clostridium difficile colonization in newborns: results using a bacteriophage and bacteriocin typing system. J Infect Dis 1988;158:349-54
20. Tullus K, Aronsson B, Marcus S, Möllby R. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 1989;8: 390-3
21. Ellis ME, Mandal BK, Dunbar EM, Bundell KR. Clostridium difficile and its cytotoxin in infants admitted to hospital with infectious gastroenteritis. Br Med J 1984;288:524-6
22. Ma°rdh PA, Helin I, Colleen I, et al. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta Paediatr Scand 1982;71:275-8
23. Vesikari T, Isolauri E, Mäki M, Grönroos P. Clostridium difficile in young children. Association with antibiotic usage. Acta Paediatr Scand 1984;73:86-91
24. Eglow R, Pothoulakis C, Itzkowitz S, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992;90:822-9
25. Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics 2013;131:196-200
26. Sharland MC, Cant A, Shingadia D. Clostridium difficile infection. In: Manual of childhood infections: the Blue Book. Oxford University Press, Oxford, UK; 2011. p. 487-95
27. Faust SN, Wilcox MH, Banaszkiewicz A, et al. Lack of evidence for an unmet need to treat Clostridium difficile infection in infants aged
28. Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012;7:e51728
29. Duleba K, Pawowska M, Wietlicka-Piszcz M. Clostridium difficile infection in children hospitalized due to diarrhea. Eur J Clin Microbiol Infect Dis 2014;33:201-9
30. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
31. Department of health and health protection agency updated guidance on the management and treatment of Clostridium difficile infection. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/321891/Clostridium-difficile-management-and-treatment.pdf [Accessed on 4 February 2015]
32. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067-79
33. Shannon-Lowe J, Matherson NJ, Cooke FJ, et al. Prevention and medical management of Clostridium difficile infection. Br Med J 2010;340:c1296
34. Pant C, Deshpande A, Altaf MA, et al. Clostridium difficile infection in children: a comprehensive review. Curr Med Res Opin 2013;29:967-84
35. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
36. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature 2014;509: 357-60
37. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol 2010;105: 2327-39
38. Orrhage K, Sjöstedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000;46: 603-12
39. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003;69:1920-7
40. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003;17: 755-73
41. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-41
42. Fitzpatrick LR. Probiotics for the treatment of Clostridium difficile associated disease. World J Gastroenterol 2013;4:47-52
43. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095
44. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011;45(Suppl):S149-53
45. Wall R, Marques TM, O'Sullivan O, et al. Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr 2012;95:1278-87
46. Dendukuri N, Brophy J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am J Gastroenterology 2007;102:201
47. Lewis S. Response to article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2007;102:201-2
48. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22
49. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157:878-88
50. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence from prophylactic or therapeutic efficacy. Anaerobe 2009;15:281-4
51. Na X, Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol 2011;45:S154-8
52. Elmer GW. Probiotics: "living drugs.". Am J Health Syst Pharm 2001;58:1101-9
53. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks Am J Clin Nutr 2006;83:1256-64; quiz 1446-7
54. Walia R, Kunde S, Mahajan L. Fecal microbiota transplantation in the treatment of refractory Clostridium difficile infection in children: an update. Curr Opin Pediatr 2014;26:573-8
55. van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol 2014;30:34-9
56. Russell G, Kaplan J, Ferraro M, et al. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010;126: e239-42
57. Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol 2012;107:1930-1
58. Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014;33:1198-200
59. Walia R, Garg S, Song Y, et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr 2014;59:565-70
60. Vandenplas Y, Veereman G, Vander Werff Ten Bosch J, et al. Fecal microbial transplantation in a one-year-old girl with early onset colitis-caution advised. J Pediatr Gastroenterol Nutr 2014. [Epub ahead of print]
61. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312:1772-8.
62. Louie T, Cannon K, O'grady H, et al. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). Abstract 89. Presented at: IDWeek 2013; 2-6 October 2013; San Francisco, California. Available from: https://idsa. confex.com/idsa/2013/webprogram/Paper41627.htm [Accessed on 4 February 2015]
63. Papin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60
64. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-70
65. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother 2007;5:48-51
66. Saito T, Kimura S, Tateda K, et al. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother 2011;66: 1096-9
67. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011;56:19-26
68. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006;74:6339-47
69. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
70. Steele J, Sponseller J, Schmidt D, et al. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother 2013;9:1565-8
71. Luciano JA, Zuckerbraun BS. Clostridium difficile infection: prevention, treatment, and surgical management. Surg Clin North Am 2014;94:1335-49.
72. Grewal NS, Salim A. Clostridium difficile colitis: a call for aggressive management. Scand J Surg 2010;99:90-2
73. Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis 2014;5: 69-84
74. Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. J Antimicrob Chemother 2013;68:1688-9
75. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
76. Joseph J, Singhal S, Patel GM, Anand S. Clostridium difficile colitis: review of the therapeutic approach. Am J Ther 2014;21: 385-94
77. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26: 17-25
78. Rea MC, Alemayehu D, Ross RP, Hill C. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J Med Microbiol 2013;62:1369-78
79. Lynch SV. Fecal microbiota transplantation for recurrent Clostridium difficile infection in pediatric patients: encouragement wrapped in caution. J Pediatr Gastroenterol Nutr 2015;60:1-3
80. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013;5:193ra91